uniQure NV
Fechado
49.16 11.52
Visão Geral
Variação de preço das ações
24h
Mín
44.17
Máximo
49.51
Rendimento | -16M -54M |
|---|---|
Vendas | -2M 3.6M |
EPS | -0.73 |
Margem de lucro | -1,502.948 |
Funcionários | 221 |
EBITDA | 13M -36M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +33.66% upside |
Próximos Ganhos | 28 de jul. de 2026 |
|---|
Capitalização de Mercado | 454M 1.8B |
|---|---|
Abertura anterior | 37.64 |
Fecho anterior | 49.16 |
uniQure NV Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
